Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator to market a generic medication for the prevention of heart attack and stroke. The company has received ...

To REMS, or not to REMS. That, apparently, was the question for Cytokinetics, which has seen any potential approval for its ...